ArticleFocus (American Psychiatric Publishing)2019
Novel Formulations of Buprenorphine for Treatment of Opioid Use Disorder.
Article in Focus (American Psychiatric Publishing), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.
- Drug delivery strategies for the treatment of relapse behavior in substance use disorder- A systematic review.Metabolic brain disease · 2025Pooled it
- Long-Acting injectable buprenorphine PLGA microparticle formulation.International journal of pharmaceutics · 2025Article
- Case report: Local anesthesia with lidocaine infiltration for extended-release buprenorphine therapy.Frontiers in psychiatry · 2025Article
- Overview about Oral Films in Mental Disorders.Pharmaceuticals (Basel, Switzerland) · 2023Review
- Perception of a New Prolonged-Release Buprenorphine Formulation in Patients with Opioid Use Disorder: The PREDEPO Study.European addiction research · 2022Observational
- Buprenorphine and its formulations: a comprehensive review.Health psychology research · 2022Article
- COVID19 pandemic and people with opioid use disorder: innovation to reduce risk.Psychiatry research · 2020Article
- Progress and Future: Meeting the Needs of the Nation's Substance Use Crisis.Focus (American Psychiatric Publishing) · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid use disorder (OUD) is epidemic in the United States. In addition to medical, economic, and social impairments, risk of overdose fatality is high. In 2017, there were 14,958 deaths from natural or semisynthetic opioids, 15,958 from heroin, and 29,406 from synthetic opioids, such as fentanyl. Psychosocial interventions do not add substantial efficacy to medical OUD treatments, and thus making evidence-based OUD treatments more accessible is urgent. However, considerable diversion of oral and transmucosal opioid maintenance medications has been documented. Delivery systems that reduce risks of nonadherence through diversion or altered self-administration may increase buprenorphine's effectiveness for clinical stabilization via increased treatment exposure. The article presents findings from multisite efficacy studies of two subcutaneous depot buprenorphine formulations and a long-acting implant. Novel delivery systems show promise in providing improved outcomes through intermediate- and long-acting exposure to medication while reducing the risk of medication nonadherence, diversion, and accidental exposure.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.